Palmidrol: all 26 studies that test it
Page 1 of 1. Open to participants first (9), then studies with results posted, then the rest; newest registration first within each.
- Palmitoylethanolamide Modulates Central Sensitisation and Neuroinflammation in Chronic Low Back PainRecruitingNCT07772141Not applicable
- Intra-Articular Adelmidrol 2%/Hyaluronic Acid 1% With or Without m/umPEA, in Knee Pain Due to Joint Degeneration.Not yet recruitingNCT07680101Not applicable
- Palmitoylethanolamide in Ulcerative ColitisRecruitingNCT07609810Not applicable
- Training Health Recovery and Improvement Via Levagen+® EvaluationRecruitingNCT07359534Not applicable
- Sleep and Stress StudyRecruitingNCT07315516Phase 2
- Levagen+ Efficacy Study on Diabetic Peripheral NeuropathyRecruitingNCT07028528Phase 2
- Palmitoylethanolamide for Chronic Inflammatory Pain ConditionsRecruitingNCT06273462Phase 2
- PEA vs. Placebo for Major DepressionRecruitingNCT06063369Phase 2
- PEA in Functional DyspepsiaRecruitingNCT05877781Not applicable
- A Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar DepressionCompletedNCT06229977Phase 2Results posted
- Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)TerminatedNCT05652907Phase 2Results posted
- PEA for the Relief of Chemotherapy-Induced Peripheral NeuropathyActive, not recruitingNCT05246670Phase 2Results posted
- Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette SyndromeCompletedNCT03066193Phase 2Results posted
- Palmitoylethanolamide vs Ibuprofen for Pain After ESWLCompletedNCT07316660Not applicable
- Long-Term PEA Safety StudyActive, not recruitingNCT06717867Phase 2
- Impact of Levagen+® Palmitoylethanolamide (PEA) in a Cross-Over Trial Examining Stress and Cognition in University StudentsCompletedNCT06225440Not applicable
- Effectiveness of PEA Compared to Placebo on Acute Menstrual PainCompletedNCT05810116Phase 4
- Endocannabinoids, Stress, Craving And Pain Effects StudyCompletedNCT05480072Early Phase 1
- Mechanisms of Palmitoylethanolamide (PEA) to Alter Pain Sensitivity in Knee OsteoarthritisCompletedNCT05406726Not applicable
- Effect of Palmitoylethanolamide on Reducing Opioid Consumption for Below Knee Fracture FixationWithdrawnNCT05317676Phase 2
- Immune Diversity Response to Oral Dosing of Nutritional Health Products in Healthy ParticipantsCompletedNCT05242718Not applicable
- A Study Evaluating the Effectiveness of PEA Compared to Placebo for Reducing Pain Severity and Duration of Migraines.CompletedNCT05046522Phase 3
- Effect of Palmitoylethanolamide on Proinflammatory Markers in Adults Recently Diagnosed With COVID-19CompletedNCT04912921Not applicable
- Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19TerminatedNCT04619706Phase 2
- Effects of Palmitoylethanolamide on Inner Retinal Function in Glaucoma Patients by Pattern ElectroretinogramCompletedNCT04088084Phase 2
- Palmitoylethanolamide for Post-operative Pain PreventionStatus unknownNCT01491191Not applicable